Propranolol for Infantile Hemangiomas: Early Experience at a Tertiary Vascular Anomalies Center

被引:131
|
作者
Buckmiller, Lisa M. [1 ]
Munson, Patrick D. [1 ]
Dyamenahalli, Umesh [2 ]
Dai, Yuemeng [1 ]
Richter, Gresham T. [1 ]
机构
[1] Univ Arkansas Med Sci, Arkansas Childrens Hosp, Dept Otolaryngol, Div Pediat Otolaryngol, Little Rock, AR 72202 USA
[2] Univ Arkansas Med Sci, Arkansas Childrens Hosp, Dept Pediat, Little Rock, AR 72202 USA
来源
LARYNGOSCOPE | 2010年 / 120卷 / 04期
关键词
Propranolol; hemangioma; birthmark; beta-blocker; CLASSIFICATION; VINCRISTINE; CHILDREN; INFANCY;
D O I
10.1002/lary.20807
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objectives/Hypothesis: Propranolol has recently been introduced as a novel pharmacologic treatment for infantile hemangiomas Systematic examination of this treatment in a tertiary care setting has not been described This study explores the impact of propranolol on both proliferative and involuting hemangiomas at a tertiary vascular anomalies center. Study Design: Retrospective single institution review Materials and Methods: We reviewed children treated with propranolol for problematic hemangiomas followed by a blinded prospective analysis of serial photographs taken during the course of their therapy Parental questionnaires were obtained to evaluate perceived therapeutic response and complications to oral propranolol. Results: Thirty-two children with complete photo documentation were treated with oral propranolol for infantile hemangiomas between September 2008 and June 2009 Twenty-seven patients began therapy during the proliferative phase of their lesions (mean age, 4 9 months), whereas five patients began during the involutional phase (mean age, 19.4 months) Ninety-seven percent of patients displayed improvement in the quality of their hemangiomas during propranolol therapy Patients were determined to be excellent responders (n = 16, 50%), partial responders (n = 15, 47%), or nonresponders (n = 1, 3%) Partial and nonresponders received adjuvant therapy (75%, laser therapy; 31%, steroid injections). Ten patients experienced minor but reportable side effects to propranolol, including somnolence (27.2%), gastroesophageal reflux (9.1%), respiratory syncytial virus exacerbation (4.5%), and rash (4.5%). Conclusions: Propranolol may revolutionize the treatment of problematic hemangiomas that cause imminent functional or cosmetic sequelae. At therapeutic doses, propranolol is safe and effective in the majority of patients. Adjunctive therapies may still be required Minor side effects, expected from beta-blocker therapy, are common but easily managed.
引用
收藏
页码:676 / 681
页数:6
相关论文
共 50 条
  • [41] A tertiary centre experience of the use of propranolol in infantile haemangiomas
    Khan, Sabrina
    Parsons, Elizabeth
    McPherson, Tess
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 : 209 - 210
  • [42] Propranolol Treatment of Vascular Anomalies Other Than Infantile Hemangioma
    Goss, Jeremy A.
    Konczyk, Dennis J.
    Alomari, Mohammed H.
    Maclellan, Reid A.
    Greene, Arin K.
    JOURNAL OF CRANIOFACIAL SURGERY, 2017, 28 (08) : 2001 - 2003
  • [43] Propranolol Treatment of Vascular Anomalies Other Than Infantile Hemangioma
    Goss, Jeremy A.
    Konczyk, Dennis J.
    Alomari, Mohammed H.
    Maclellan, Reid A.
    Greene, Arin K.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2017, 225 (04) : S165 - S165
  • [44] Treatment for Infantile Hemangiomas: Selection Criteria, Safety, and Outcomes Using Oral Propranolol During the Early Phase of Propranolol Use for Hemangiomas
    MacIsaac, Zoe M.
    Nayar, Harry S.
    Gehris, Robin
    Mehta, Deepak
    Geisler, Susan
    Grunwaldt, Lorelei J.
    JOURNAL OF CRANIOFACIAL SURGERY, 2016, 27 (01) : 159 - 162
  • [45] Infantile hemangiomas treated with propranolol: Description of the Phoenix Children's Hospital experience
    Speetzen, Larisa
    Price, Harper
    O'Haver, Judy
    Reinesch, Kellie
    Patel, Nirav
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB164 - AB164
  • [46] Vascular anomalies: Hemangiomas
    Gampper, TJ
    Morgan, RF
    PLASTIC AND RECONSTRUCTIVE SURGERY, 2002, 110 (02) : 572 - 585
  • [47] Infantile Hemangiomas of the Head and Neck: A Single-Center Experience
    Kizmazoglu, Deniz
    Ince, Dilek
    Olgun, Yuksel
    Cecen, Emre
    Guleryuz, Handan
    Erdag, Taner
    Olgun, Nur
    CHILDREN-BASEL, 2024, 11 (03):
  • [48] Commentary: Propranolol for infantile hemangiomas - The intralesional route
    Tripathy, Devjyoti
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2019, 67 (12) : 1981 - 1982
  • [49] THE PLACE OF PROPRANOLOL AND CORTIOCOSTEROIDS IN THE TREATMENT OF INFANTILE HEMANGIOMAS
    Poetke, M.
    Muller, U.
    Urban, P.
    Carsten, P.
    Rossi, R.
    Berlien, P. H.
    ACTA PAEDIATRICA, 2010, 99 : 45 - 45
  • [50] Effect of propranolol on sleep in children with infantile hemangiomas
    Saddi, V.
    Frost, S.
    Williamson, B.
    Mallit, K. -A.
    Wargon, O.
    Teng, A.
    JOURNAL OF SLEEP RESEARCH, 2019, 28